FDA Adverse Event Malfunction Summary report: N

UNICEL DXI 800 ACCESS® IMMUNOASSAY SYSTEM

MDR report key: 2192383 · Received August 5, 2011

Report

Report Number
2122870-2011-02675
Event Type
Malfunction
Date Received
August 5, 2011
Date of Event
July 5, 2011
Report Date
July 5, 2011
Manufacturer
BECKMAN COULTER, INC.
Product Code
JJE
PMA / PMN Number
K023764
Removal / Correction Number
NA
Product Problem
Yes
Report Source
Manufacturer report
Reporter Location
CA
Reporter Occupation
OTHER

Narratives

Additional Manufacturer Narrative · 1

PATIENT SAMPLE WAS COLLECTED IN A LITHIUM HEPARIN PLASMA TUBE AND CENTRIFUGED IN A POWER PROCESSOR CENTRIFUGE FOR 4 MINUTES. ACCUTNI CALIBRATION PERFORMED ON (B)(6) 2011 PASSED. SYSTEM CHECK PERFORMED ON (B)(6) 2011 ALSO PASSED. LEVELS 1 AND 3 ACCUTNI QC WAS WITHIN THE CUSTOMER'S ESTABLISHED RANGES ON THE DATE OF EVENT. A BEC FIELD SERVICE ENGINEER (FSE) WAS DISPATCHED ON (B)(6) 2011 FOR THE EVENT. THE FSE REPLACED THE PARTICLE PUMP AND THE 2 WASH PUMPS. THE FSE ALSO RAN A SYSTEM CHECK AND A HIGH SENSITIVITY SYSTEM CHECK, WHICH PASSED. ALTHOUGH HARDWARE ISSUES WERE ADDRESSED, A CLEAR ROOT CAUSE COULD NOT BE DETERMINED FOR THIS EVENT.

Description of Event or Problem · 1

A CUSTOMER CONTACTED BECKMAN COULTER, INC. (BEC) TO REPORT OBTAINING AN ERRONEOUS TROPONIN (ACCUTNI) RESULT WITHIN THE RISK STRATIFICATION RANGE FOR ONE (1) PATIENT. THE ELEVATED ACCUTNI RESULT WAS GENERATED ON A UNICEL DXI 800 ACCESS IMMUNOASSAY SYSTEM, USED IN CONJUNCTION WITH ACCESS ACCUTNI REAGENT (LOT 110410) AND ACCESS ACCUTNI CALIBRATOR (LOT 023153). SUBSEQUENT TESTING ON THE SAME INSTRUMENT PRODUCED A LOWER RESULT WITHIN THE NORMAL REFERENCE RANGE. RESULTS ARE SHOWN. THE ELEVATED ACCUTNI RESULT WAS REPORTED OUT OF THE LAB. THE CUSTOMER WAS UNSURE IF PATIENT TREATMENT WAS CHANGED DUE TO REPORTED ERRONEOUS RESULT.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
1 UNICEL DXI 800 ACCESS® IMMUNOASSAY SYSTEM DISCRETE PHOTOMETRIC CHEMISTRY ANALYZER FOR CLINICAL USE JJE BECKMAN COULTER, INC. DXI 800 NA

Patients

Seq Age Sex Outcome Treatment
1